**Supplemental Table 1. Level of PT prolongation,** **TBIL, PA and Alb in HCC patients with different background**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **PT prolongation, s** | | **TBIL, μmol/L** | | **Alb, g/L** | | **PA,** **mg/L** | |
|  |  | **Mean ± SD** | ***p*** | **Mean ± SD** | ***p*** | **Mean ± SD** | ***p*** | **Mean ± SD** | ***p*** |
| Age | <60 | 1.61±2.04. | 0.308 | 17.65±21.30 | 0.818 | 40.77±5.04 | 0.043 | 157.57±54.16 | 0.164 |
| ≥60 | 1.42±1.68 |  | 17.20±12.74 |  | 39.72±6.33 |  | 142.83±52.38 |  |
| Sex | M | 1.62±1.75 | 0.241 | 17.78±20.95 | 0.528 | 40.18±6.05 | 0.342 | 151.41±53.82 | 0.005 |
| F | 1.37±2.73 |  | 16.48±12.58 |  | 39.63±4.91 |  | 134.91±48.47 |  |
| HBV or HCV | - | 0.90±1.19 | <0.001 | 17.46±18.06 | 0.727 | 41.76±5.62 | 0.010 | 175.85±62.16 | <0.001 |
| +\* | 1.67±1.93 |  | 18.20±26.79 |  | 40.27±5.30 |  | 150.94±50.63 |  |
| BCLC | A | 1.50±1.89 | 0.241 | 17.56±20.99 | 0.980 | 40.53±5.15 | 0.956 | 158.63±54.44 | 0.007 |
| B | 1.93±2.33 |  | 17.50±10.73 |  | 40.56±6.43 |  | 141.54±48.27 |  |
| Child-Pugh | A | 1.28±1.46 | <0.001 | 14.87±7.39 | <0.001 | 41.11±4.99 | <0.001 | 160.11±53.03 | <0.001 |
| B | 3.86±3.41 |  | 38.88±50.70 |  | 35.91±6.06 |  | 120.23±46.95 |  |

+: positive for either hepatitis B surface antigen or anti-HCV; -: negative for both hepatitis B surface antigen and anti-HCV.

Abbreviations: Alb, albumin; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PA, prealbumin; PT, prothrombin time; TBIL, total bilirubin.